Market Watch
A snapshot of what’s happening across the industry—a one-stop source for key developments across policy and regulatory changes, service and treatment innovations, technological advancements, industry recognition and accreditation, mergers and acquisitions, leadership shifts, and more.
Filter Options
-
By Categories
-
By Date Range
-
Sort Date By
-
Results Per Page
Clear Filters
-
Solera Health Launches Intervention-Based Behavioral Health Network To Expand Whole-Person Care
March 3, 2026Solera Health, a digital health delivery company creating flexible solutions to connect people to on-benefit care via health plans and employers, announced the launch of its new Behavioral Health network. The network offers an intervention-based, whole-person approach designed to expand… -
NAMI Launches Initiative To Assess Clarity & Safety Of AI Mental Health Tools
March 3, 2026The National Alliance on Mental Illness (NAMI), a grassroots mental health advocacy non-profit in the United States, is launching an initiative to develop benchmarks for assessing how artificial intelligence (AI) tools respond when people seek mental health information and support.… -
Horizon Behavioral Health Awarded $1.1 Million SAMHSA Grant To Expand Substance Use Treatment & Recovery Services In Appomattox County, Virginia
March 3, 2026Horizon Behavioral Health announced that it has been awarded a $1,125,000 Targeted Capacity Expansion (TCE) grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) to expand evidence-based substance use disorder (SUD) treatment and recovery supports in Appomattox County,… -
Pearl Unveils Annie, A Specialized Online Mental Wellness Platform, Expanding Mental Health Support In The U.S.
March 3, 2026Pearl, a company providing online professional service platforms, introduced Annie, its latest specialized platform. Annie is a free, online mental wellness offering for the United States that combines an empathetic artificial intelligence (AI) chatbot with direct access to vetted human… -
Beachcomber IOP Launches Virtual Intensive Outpatient Program To Expand Access To Addiction Treatment In Florida
March 3, 2026Beachcomber IOP, a family-owned addiction treatment provider organization in Florida, announced the launch of a Virtual Intensive Outpatient Program (Virtual IOP). The program expands access to structured, evidence-based addiction treatment for individuals seeking flexible remote care. The newly launched Virtual… -
UK Mental Health Association, Mind Launches ‘AI & Mental Health Commission’
March 2, 2026Mind, the national association for mental health in the United Kingdom (UK), announced that it will be launching an “AI and Mental Health Commission.” The commission will run for one year and aims to address concerns about artificial intelligence (AI)… -
Parc Center For Disabilities Announces Children’s Services Center Opening
March 2, 2026Parc Center for Disabilities (Parc), a Tampa Bay area organization providing lifelong support for individuals with intellectual and developmental disabilities, announced the grand opening of the Tom & Mary James Children’s Services Center. The new center supports Parc’s commitment to… -
FDA Accepts Teva’s New Drug Application For Olanzapine Extended-Release Injectable Suspension For The Once-Monthly Treatment Of Schizophrenia In Adults
March 2, 2026Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Medincell announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-‘749) for the treatment of schizophrenia in… -
CFG Health Launches CareLink, A Fully Integrated, 24/7 Telehealth Platform For Correctional Health Care
March 2, 2026CFG Health, which provides regional correctional health care services, launched CFG CareLink, a proprietary, in-house telehealth platform for technology-enabled correctional health care. The platform includes secure tablet devices that connect to a virtual care infrastructure. The virtual services are delivered… -
Compass Pathways Reports Positive Outcomes From Second Phase 3 Trial Evaluating COMP360 Psilocybin For Treatment-Resistant Depression
March 2, 2026Compass Pathways plc, a biotechnology company developing a psilocybin compound for treatment-resistant depression, reported positive outcomes from its second Phase 3 clinical trial. The trial evaluated two doses of COMP360, a synthetic, proprietary formulation of psilocybin. The primary endpoint was…
3051 Results | Page 1 of 306